ืืฃ ืืืืชGUD โข TSE
add
Knight Therapeutics Inc
trending_downืืืืื ืืืคืกืืืืื ืืื ืืืจ ืขืจื ืฉืจืฉืื ืCAืืืฉืจื ืืจืืฉื ืฉื ืืืืจื ื ืืฆื ืCA
ืฉืขืจ ืกืืืจื ืงืืื
โ6.05ย โ$
ืืืื ืืืื
โ5.91ย โ$ - โ6.05ย โ$
ืืืื ืฉื ืชื
โ5.25ย โ$ - โ6.55ย โ$
ืฉืืื ืฉืืง
586.63Mโ CAD
ื ืคื ืืกืืจ ืืืืฆืข
44.88Kโ
ืืืคืื ืจืืื
-
ืชืฉืืืช ืืืืืื ื
-
ืืืจืกื ืขืืงืจืืช
TSE
ืืืฉืืช ืฉืืง ืืืื
ืืกืคืื
ืืฆืืจืช ืืื ืกื
ืืื ืกื
ืจืืื ื ืงื
| (CAD) | ืกืคืืณ 2025info | ืฉืื ืื ืืฉื ื ืืฉื ื |
|---|---|---|
ืืื ืกื | 121.55Mโ | 31.74% |
ืืืฆืืืช ืชืคืขืืืืืช | 55.16Mโ | 31.93% |
ืจืืื ื ืงื | โ-3.79Mโ | โ-4,560.00% |
ืฉืืื ืจืืื ื ืงื | โ-3.12 | โ-3,566.67% |
ืจืืืืื ืืื ืื | โ-0.02 | โ |
ืจืืื ืืคื ื ืจืืืืช, ืืืกืื, ืคืืช ืืืคืืชืืช | 18.41Mโ | 10.98% |
ืฉืืขืืจ ืืก ืืคืงืืืื | โ-97.76% | โ |
ืืืื
ืกื ืื ืื ืืกืื
ืืืืช ืืืืืช
| (CAD) | ืกืคืืณ 2025info | ืฉืื ืื ืืฉื ื ืืฉื ื |
|---|---|---|
ืืืืื ืื ืืืฉืงืขืืช ืืืืื ืงืฆืจ | 118.14Mโ | โ-31.44% |
ืกื ืื ืื ืืกืื | 1.05Bโ | 8.97% |
ืืืืช ืืืืืช | 281.78Mโ | 49.58% |
ืืื ืขืฆืื ืืืื | 766.79Mโ | โ |
ืืื ืขืืื | 99.29Mโ | โ |
ืืืคืื ืืื | 0.79 | โ |
ืชืฉืืื ืขื ืื ืืกืื | 0.15% | โ |
ืชืฉืืื ืขื ืืื | 0.19% | โ |
ืชืืจืื ืืืืื ืื
ืฉืื ืื ืืฉืืื ืืืืื ืื
| (CAD) | ืกืคืืณ 2025info | ืฉืื ืื ืืฉื ื ืืฉื ื |
|---|---|---|
ืจืืื ื ืงื | โ-3.79Mโ | โ-4,560.00% |
ืืืืื ืื ืืคืขืืืืช ืฉืืืคืช | 10.16Mโ | 102.61% |
ืืืืื ืืืฉืงืขืืช | โ-1.41Mโ | โ-112.20% |
ืืืืื ืืืืืื | โ-5.91Mโ | โ-50.47% |
ืฉืื ืื ืืฉืืื ืืืืื ืื | 4.06Mโ | โ-68.64% |
ืชืืจืื ืืืืื ืื ืคื ืื | โ-3.92Mโ | โ-484.53% |
ืืืืข ืืืื
Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange, with a market capitalization of $1.02 billion as of August 2019. Wikipedia
ืชืืจืื ืืงืื
2014
ืืฉืจืืื ืจืืฉืืื
ืืชืจ
ืขืืืืื
745
